Immunogenicity of Recombinant Human Interleukin-3

Overview

Journal Clin Immunol Immunopathol

Specialty Allergy & Immunology

Date 1997 Apr 1

PMID 9073525

Citations 4

Authors

H Gunn

Affiliations

Soon will be listed here.

Abstract

Most recombinant human (rh) proteins elicit an immune response in experimental animals. Antibodies are usually detected within 1 to 2 weeks of protein administration. The immunogenicity of rh proteins is an important aspect for both experimental and clinical investigations. The formation of neutralizing antibodies-as shown here for rhIL-3-reduced the absolute bioavailability of the protein in Rhesus monkeys.

Citing Articles

Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.

Menochet K, Yu H, Wang B, Tibbitts J, Hsu C, Kamath A MAbs. 2022; 14(1):2145997.

PMID: 36418217 PMC: 9704389. DOI: 10.1080/19420862.2022.2145997.

Immunogenicity of Protein Pharmaceuticals.

Dingman R, Balu-Iyer S J Pharm Sci. 2019; 108(5):1637-1654.

PMID: 30599169 PMC: 6720129. DOI: 10.1016/j.xphs.2018.12.014.

Preclinical models used for immunogenicity prediction of therapeutic proteins.

Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S Pharm Res. 2013; 30(7):1719-28.

PMID: 23649852 DOI: 10.1007/s11095-013-1062-z.

Immunogenicity of therapeutic proteins: the use of animal models.

Brinks V, Jiskoot W, Schellekens H Pharm Res. 2011; 28(10):2379-85.

PMID: 21744171 PMC: 3170476. DOI: 10.1007/s11095-011-0523-5.